Literature DB >> 27439327

[Interaction of opioid analgesics at the level of biotransformation].

H Petri1, D Grandt2.   

Abstract

Opioids are an important component of the drug treatment of patients with acute and chronic pain. They differ in effectiveness, side effect profile and the risk of interactions. In this article the pharmacokinetic mechanisms of drug-drug interactions at the level of biotransformation are described and the clinical consequences which can arise are discussed. The relation of the active components to the two isoenzymes CYP2D6 and CYP3A4 is of major importance for assessing the potential drug-drug interactions of opioid analgesics at the level of the cytochrome P450 enzyme.

Entities:  

Keywords:  Cytochrome P450 (CYP); Drug-drug interaction; Hepatic metabolism; Opioids; Pain

Mesh:

Substances:

Year:  2016        PMID: 27439327     DOI: 10.1007/s00482-016-0141-6

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  43 in total

1.  Fentanyl-clarithromycin interaction.

Authors:  Breda Cronnolly; Helen Pegrum
Journal:  BMJ Case Rep       Date:  2012-07-09

2.  Possible fluconazole-fentanyl interaction-a case report.

Authors:  Pär Hallberg; Leif Martén; Mia Wadelius
Journal:  Eur J Clin Pharmacol       Date:  2006-04-21       Impact factor: 2.953

3.  Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine.

Authors:  Barbara Grün; Ulrike Merkel; Klaus-Dieter Riedel; Johanna Weiss; Gerd Mikus
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

Review 4.  Dihydrocodeine as an opioid analgesic for the treatment of moderate to severe chronic pain.

Authors:  Wojciech Leppert
Journal:  Curr Drug Metab       Date:  2010-07       Impact factor: 3.731

5.  Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor.

Authors:  C Gillen; M Haurand; D J Kobelt; S Wnendt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-08       Impact factor: 3.000

6.  Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients.

Authors:  Elinore F McCance-Katz; David E Moody; Sudha Prathikanti; Gerald Friedland; Petrie M Rainey
Journal:  Drug Alcohol Depend       Date:  2011-05-19       Impact factor: 4.492

7.  Ritonavir's role in reducing fentanyl clearance and prolonging its half-life.

Authors:  K T Olkkola; V J Palkama; P J Neuvonen
Journal:  Anesthesiology       Date:  1999-09       Impact factor: 7.892

8.  Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are co-administered with morphine.

Authors:  Yusuke Hara; Miki Nakajima; Ken-ichi Miyamoto; Tsuyoshi Yokoi
Journal:  Drug Metab Pharmacokinet       Date:  2007-04       Impact factor: 3.614

9.  Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone.

Authors:  Teijo I Saari; Juha Grönlund; Nora M Hagelberg; Mikko Neuvonen; Kari Laine; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2010-04       Impact factor: 2.953

10.  Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.

Authors:  Elinore F McCance-Katz; David E Moody; Gene D Morse; Qing Ma; Robin DiFrancesco; Gerald Friedland; Patricia Pade; Petrie M Rainey
Journal:  Drug Alcohol Depend       Date:  2007-07-23       Impact factor: 4.492

View more
  2 in total

1.  [Side effects of pain therapy : Sufficient analgesia without unnecessary complications].

Authors:  F Greul; A Zimmer; W Meißner
Journal:  Urologe A       Date:  2017-04       Impact factor: 0.639

2.  [Recommendations of the second update of the LONTS guidelines : Long-term opioid therapy for chronic noncancer pain].

Authors:  Winfried Häuser; Frietjof Bock; Michael Hüppe; Monika Nothacker; Heike Norda; Lukas Radbruch; Marcus Schiltenwolf; Matthias Schuler; Thomas Tölle; Annika Viniol; Frank Petzke
Journal:  Schmerz       Date:  2020-06       Impact factor: 1.107

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.